Michael Ulz

Stock Analyst at Baird

(4.04)
# 472
Out of 4,851 analysts
115
Total ratings
50%
Success rate
12.78%
Average return
Main Sectors:
Top Industries:

Stocks Rated by Michael Ulz

Karyopharm Therapeutics
May 13, 2025
Maintains: Outperform
Price Target: $54$42
Current: $4.25
Upside: +888.24%
Silence Therapeutics
May 9, 2025
Maintains: Overweight
Price Target: $45$25
Current: $5.41
Upside: +362.11%
Viking Therapeutics
Apr 24, 2025
Maintains: Overweight
Price Target: $105$102
Current: $26.61
Upside: +283.31%
Alnylam Pharmaceuticals
Apr 11, 2025
Maintains: Equal-Weight
Price Target: $284$268
Current: $303.77
Upside: -11.78%
Kyverna Therapeutics
Apr 1, 2025
Maintains: Overweight
Price Target: $40$20
Current: $2.79
Upside: +616.85%
Cabaletta Bio
Apr 1, 2025
Maintains: Overweight
Price Target: $30$22
Current: $2.18
Upside: +909.17%
Aardvark Therapeutics
Mar 10, 2025
Initiates: Overweight
Price Target: $29
Current: $11.66
Upside: +148.71%
Y-mAbs Therapeutics
Mar 5, 2025
Maintains: Underweight
Price Target: $11$7
Current: $4.88
Upside: +43.44%
Iovance Biotherapeutics
Feb 28, 2025
Maintains: Outperform
Price Target: $24$20
Current: $1.82
Upside: +998.90%
Third Harmonic Bio
Feb 12, 2025
Downgrades: Equal-Weight
Price Target: $20$5
Current: $5.25
Upside: -4.76%
Maintains: Overweight
Price Target: $18$10
Current: $1.95
Upside: +412.82%
Maintains: Overweight
Price Target: $46$96
Current: $51.68
Upside: +85.76%
Maintains: Overweight
Price Target: $48$52
Current: $13.27
Upside: +291.86%
Maintains: Equal-Weight
Price Target: $110$115
Current: $127.60
Upside: -9.87%
Maintains: Overweight
Price Target: $53$57
Current: $45.29
Upside: +25.86%
Maintains: Equal-Weight
Price Target: $36$27
Current: $16.61
Upside: +62.55%
Maintains: Equal-Weight
Price Target: $3$7
Current: $1.36
Upside: +414.71%
Maintains: Equal-Weight
Price Target: $45$48
Current: $34.76
Upside: +38.09%
Maintains: Outperform
Price Target: $15$27
Current: $8.40
Upside: +221.43%
Maintains: Equal-Weight
Price Target: $30$20
Current: $3.15
Upside: +534.92%
Initiates: Overweight
Price Target: $45
Current: $2.96
Upside: +1,420.27%
Maintains: Overweight
Price Target: $20$10
Current: $0.68
Upside: +1,379.51%
Downgrades: Equal-Weight
Price Target: $3
Current: $2.78
Upside: +7.91%
Upgrades: Equal-Weight
Price Target: $18$30
Current: $5.23
Upside: +473.61%
Maintains: Equal-Weight
Price Target: $25$30
Current: $1.25
Upside: +2,309.64%
Initiates: Outperform
Price Target: $45
Current: $10.11
Upside: +345.32%
Maintains: Outperform
Price Target: $12$20
Current: $0.35
Upside: +5,633.94%
Maintains: Outperform
Price Target: $85$80
Current: $36.40
Upside: +119.78%
Maintains: Outperform
Price Target: $12$15
Current: $6.27
Upside: +139.43%